What is SCLX's current stock price?

SCLX (Scilex Holding Company) is currently trading at $6.11 with a market cap of $51.9M.

What sector is Scilex Holding Company in?

Scilex Holding Company (SCLX) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

InvestLog

SCLX Scilex Holding Company

Healthcare

$6.11+3.21%ClosedMarket Cap: $51.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-0.17

P/S

1.53

EV/EBITDA

-0.43

DCF Value

$-47.25

FCF Yield

-12.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

55.0%

Operating Margin

-817.1%

Net Margin

-1239.4%

ROE

190.1%

ROA

-142.9%

ROIC

230.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$8.6M	$-43.3M	$—
Q4 null	$4.8M	$-33.1M	$—
FY null	$30.3M	$-358.7M	$—
Q3 null	$10.6M	$-257.2M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Ma Stephen Hoidirector, officer: CFO, COO and Secretary

BuyMon Apr 20

Ji Henrydirector, officer: Exec Chair, CEO and President

SellMon Apr 20

Ji Henrydirector, officer: Exec Chair, CEO and President

BuyMon Apr 20

Scilex Holding Co10 percent owner

SellTue Dec 30

Scilex Holding Co10 percent owner

SellTue Dec 30

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

Exchange

—

Beta

1.78

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Peers

INO

IRD